Michael Owens
Director of Finance/CFO at ONCOZENGE AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Anders Bergman | M | 60 |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Sten Gunnar Otto Skolling | M | 63 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | 4 years |
| Karl Fredrik Sjövall | M | 44 |
Emollivet AB
| 6 years |
| Jack Spira | M | 71 | - | |
| Gunilla Lundmark | F | 61 | 5 years | |
| Erik Anders Kronström | M | 57 | 10 years | |
| Daniel Ehrenstråhle | M | 50 | 1 years | |
| Christoph Nowak | M | 38 | 1 years | |
| James Hall | M | - |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Ola Holmlund | M | 55 | 6 years | |
| Eva Idén | F | 58 | 7 years | |
| Kristina Sjöblom Nygren | M | 63 | 6 years | |
| Staffan Strömberg | M | 57 | 11 years | |
| Anthon Jahreskog | M | 44 | 7 years | |
| Niclas Holmgren | M | 32 | 1 years | |
| Markus Jerling | M | 72 | 3 years | |
| Knut Pettersson | M | - |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Margareta Hagman | F | 58 | 9 years | |
| Anna Carina Schmidt | F | 66 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Jonas Rastad | M | 74 | - | |
| Denis Angioletti | M | 56 | 4 years | |
| Tony Brejke | M | - | - | |
| Maria Wikstrom | F | - | - | |
| Philip Slatis | M | - | 2 years | |
| Maria Ekdahl | F | 51 | 2 years | |
| Eva Montgomerie | F | 66 | 17 years | |
| Per Holm | M | - | 9 years | |
| Stian Kildal | M | - | 1 years | |
| Anders Hagman | M | - | 4 years | |
| Carl Johan Kördel | M | 62 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Jostein Davidsen | M | 65 | - | |
| Agneta Heierson | M | - | - | |
| Leif Gallo | M | 65 | - | |
| Peter Michael Rothschild | M | 74 | 13 years | |
| Staffan Schüberg | M | 55 |
Dizlin Pharmaceuticals AB
| - |
| Åsa Kristina Hansdotter | F | 50 |
Dizlin Pharmaceuticals AB
| - |
| Svein Arild Mathisen | M | 68 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Lars Hjarrand | M | 51 | - | |
| Gunnar Olof Olsson | M | 71 |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | - |
| Charlotta Ekman | F | 43 | 2 years | |
| Kathrine Elisabeth Andreassen | F | 58 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Mackey | M | 50 | - | |
| Peter Sjöstrand | M | 78 | 4 years | |
| Fabian Benjamin Christoffer Nordin | M | 50 | - | |
| Ulf Göran Richenberg | M | 69 | 12 years | |
| Eamonn Connolly | M | 67 | 8 years | |
| Anders Olof Adolf Ekblom | M | 70 | 5 years | |
| Ulrica Slåne Bjerke | F | 59 | 5 years | |
| Ray Hill | M | 79 | - | |
| Per-Olof Edin | M | 84 | 7 years | |
| Terje Kalland | M | 73 | 4 years | |
| Lilian Birgitta Wikström | M | 63 | 1 years | |
| Michael Wilhelm Rosenlew | M | 65 | 2 years | |
| Robert Molander | M | 59 | 4 years | |
| Hans-Peter Torsten Ekre | M | 74 | 9 years | |
| Carl Harald Janson | M | 66 | - | |
| Marek Poszepczynski | M | - | 2 years | |
| Erik Kinnman | M | 66 | 2 years | |
| Stig Lennart Hansson | M | 68 | 2 years | |
| Daniel Bolanowski | M | 42 | 5 years | |
| Stig Michael Sundström | M | 61 | 3 years | |
| Per Nilsson | M | 49 | - | |
| Torbjørn Bjerke | M | 61 | 3 years | |
| Christine Nguy | M | - | - | |
| Marie-Louise Alamaa | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 65 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Owens
- Personal Network
